Literature DB >> 27770215

Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.

George J Greene1,2, Greg Swann1,2, Angela J Fought3, Alex Carballo-Diéguez4, Thomas J Hope5, Patrick F Kiser6, Brian Mustanski1,2, Richard T D'Aquila7.   

Abstract

HIV prevention method preferences were evaluated among 512 U.S. men who have sex with men (MSM; median age: 22 years). Approximately 90 % consistently preferred one option across pairwise comparisons of condoms, daily oral pre-exposure prophylaxis (PrEP), and long-acting PrEP delivered via either an injectable or one of two types of PrEP implants differing in visibility. Condoms were most frequently preferred (33.8 %), followed by non-visible implants (21.5 %), and oral PrEP (17.0 %); HIV risk was reported by more choosing implants. In a follow-up question comparing the four PrEP options only, daily oral pills and non-visible implants were most frequently preferred (35.5 and 34.3 %, respectively), followed by injections (25.2 %) and visible implants (4.3 %). An inductive, open-coding approach determined that convenience, duration of protection, and privacy were the most commonly cited reasons for a PrEP method choice, and associated with self-report of HIV risk. Tailoring PrEP product development to privacy and other concerns important to those at highest HIV risk may improve HIV prevention.

Entities:  

Keywords:  HIV; Homosexuality; Male; Pre-exposure prophylaxis; Prevention; Sexual behavior

Mesh:

Year:  2017        PMID: 27770215      PMCID: PMC5380480          DOI: 10.1007/s10461-016-1565-9

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  50 in total

1.  Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men.

Authors:  Sarit A Golub; William Kowalczyk; Corina L Weinberger; Jeffrey T Parsons
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

2.  Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006.

Authors:  Andrew C Voetsch; James D Heffelfinger; Elin B Begley; Krishna Jafa-Bhushan; Patrick S Sullivan
Journal:  J Acquir Immune Defic Syndr       Date:  2007-11-01       Impact factor: 3.731

3.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education.

Authors:  Matthew J Mimiaga; Patricia Case; Carey V Johnson; Steven A Safren; Kenneth H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

6.  PrEP awareness and perceived barriers among single young men who have sex with men.

Authors:  Jose A Bauermeister; Steven Meanley; Emily Pingel; Jorge H Soler; Gary W Harper
Journal:  Curr HIV Res       Date:  2013-10       Impact factor: 1.581

7.  Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.

Authors:  Thesla Palanee-Phillips; Katie Schwartz; Elizabeth R Brown; Vaneshree Govender; Nyaradzo Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Sarita Naidoo; Arendevi Pather; Jessica Phillip; Marla J Husnik; Ariane van der Straten; Lydia Soto-Torres; Jared Baeten
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

Review 8.  Long-acting antiviral agents for HIV treatment.

Authors:  David A Margolis; Marta Boffito
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

Review 9.  New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.

Authors:  Marta Boffito; Akil Jackson; Andrew Owen; Stephen Becker
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321

View more
  56 in total

1.  Injection drug use, unknown HIV positive status, and self-reported current PrEP use among Black men who have sex with men attending U.S. Black pride events, 2014-2017.

Authors:  Jessica L Maksut; Rachel E Gicquelais; Kevon-Mark Jackman; Lisa A Eaton; M Revel Friedman; Derrick D Matthews; Leigh A Bukowski; Ron D Stall
Journal:  Drug Alcohol Depend       Date:  2019-12-16       Impact factor: 4.492

2.  Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

Authors:  Corrine Ying Xuan Chua; Priya Jain; Andrea Ballerini; Giacomo Bruno; R Lyle Hood; Manas Gupte; Song Gao; Nicola Di Trani; Antonia Susnjar; Kathryn Shelton; Lane R Bushman; Marco Folci; Carly S Filgueira; Mark A Marzinke; Peter L Anderson; Ming Hu; Pramod Nehete; Roberto C Arduino; Jagannadha K Sastry; Alessandro Grattoni
Journal:  J Control Release       Date:  2018-08-06       Impact factor: 9.776

3.  Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?

Authors:  Steven A John; Thomas H F Whitfield; H Jonathon Rendina; Jeffrey T Parsons; Christian Grov
Journal:  AIDS Behav       Date:  2018-04

4.  Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review.

Authors:  Benedikt Pleuhs; Katherine G Quinn; Jennifer L Walsh; Andrew E Petroll; Steven A John
Journal:  AIDS Patient Care STDS       Date:  2020-02-28       Impact factor: 5.078

5.  Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.

Authors:  Kevin M Maloney; Adrien Le Guillou; Robert A Driggers; Supriya Sarkar; Emeli J Anderson; Amyn A Malik; Samuel M Jenness
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

6.  Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China.

Authors:  Kathrine Meyers; Yumeng Wu; Haoyu Qian; Theodorus Sandfort; Xiaojie Huang; Junjie Xu; Jing Zhang; Wei Xia; David Glidden; Hao Wu; Hong Shang
Journal:  AIDS Behav       Date:  2018-04

7.  Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men.

Authors:  Thomas H F Whitfield; Steven A John; H Jonathon Rendina; Christian Grov; Jeffrey T Parsons
Journal:  AIDS Behav       Date:  2018-11

8.  MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.

Authors:  Herana Kamal Seneviratne; Craig W Hendrix; Edward J Fuchs; Namandjé N Bumpus
Journal:  J Pharmacol Exp Ther       Date:  2018-07-23       Impact factor: 4.030

9.  Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.

Authors:  Brandon D L Marshall; William C Goedel; Maximilian R F King; Alyson Singleton; David P Durham; Philip A Chan; Jeffrey P Townsend; Alison P Galvani
Journal:  Lancet HIV       Date:  2018-06-13       Impact factor: 12.767

10.  MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication.

Authors:  Katie B Biello; Matthew J Mimiaga; Christopher M Santostefano; David S Novak; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.